How to Get the Best Results on Wegovy — the Clinical Route, Explained

What the STEP 1 trial actually tells us about results

The place to start is the trial data itself. STEP 1, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg alongside lifestyle support achieved around 15% average body-weight reduction; those assigned to placebo, with identical lifestyle guidance, lost around 2.4%. That gap is striking, but so is what it confirms: lifestyle support was present for everyone, and results tracked with how consistently participants stayed on the programme.

This matters practically. The trial wasn't testing the injection in isolation, it was testing the injection as part of a structured approach. Participants who engaged with diet and activity guidance alongside their doses saw the strongest outcomes. If you're researching how to get the best results from semaglutide more broadly, the evidence points in the same direction: the medicine works by reducing appetite and slowing how quickly your stomach empties, and what you do with that reduced appetite shapes the outcome.

NICE recommends Wegovy for adults with a BMI of 35 or above alongside at least one weight-related condition, used for a maximum of two years within a specialist weight management service. NICE technology appraisal TA875 sets out those criteria in full. For people who don't meet NHS thresholds or can't wait for a referral, a regulated private pharmacy is the legal alternative, subject to the same clinical eligibility assessment.

The only legal route to Wegovy in the UK

Wegovy is a Prescription-Only Medicine under the Human Medicines Regulations 2012. That means it cannot legally be supplied without a prescription issued following a clinical assessment. Full stop. Social media sellers, unlicensed websites, and listings that appear to sidestep this requirement are not offering genuine Wegovy through a legitimate supply chain, and the MHRA has been explicit about the risks involved.

The safe route is straightforward. A registered prescriber assesses you. If clinically suitable, they issue a prescription. A GPhC-registered pharmacy dispenses it from licensed UK stock. You can verify any online pharmacy on the GPhC register before you hand over any personal or medical information. For nume, our registration number is 9012878. If a pharmacy isn't on that register, don't use it.

The MHRA has warned publicly about counterfeit weight-loss pens circulating online and via social media, fake pens have in some cases contained insulin, leading to hospitalisations. Sellers offering these medicines without a prescription, at prices far below the private market, or via direct message are red flags. Report anything suspicious at the Yellow Card scheme. For anyone serious about getting Wegovy safely, verification is the first step, not an afterthought.

How the nume consultation works, and what happens after approval

Starting with nume takes a few minutes. You complete a free clinical consultation online, covering your medical history, current medicines, BMI, and any weight-related conditions. A GPhC-registered Independent Prescriber reviews it the same day. Identity is verified with photo ID, and weight is confirmed via a brief video check, that live verification step is one of the things that distinguishes a clinically serious service from a tick-box one.

If your prescriber approves treatment, orders placed before 12pm go out the same day. A DPD tracking notification arrives on your phone, and your pen turns up the next working day in a plain box that gives nothing away. The pen itself is a pre-filled Novo Nordisk device: you'll find the patient information leaflet inside the box, and that leaflet (together with your prescriber's guidance) is your authoritative source on injection technique, storage, and what to do if you miss a dose. Our FAQs cover common aftercare questions, and prescribers are available for follow-up seven days a week.

There is no subscription. Every repeat order is clinically reviewed before it goes out. Dose increases require evidence, that policy protects you, not just our processes. If you want to understand what the real-world outcomes on Wegovy look like beyond the trial data, or explore how the clinical evidence compares across the programme, our Wegovy trial results page goes into that in detail.

Who is eligible, and what to expect at your assessment

For private treatment, the licensed eligibility criteria follow the Wegovy SmPC: adults aged 18 or over with a BMI of 30 or above, or a BMI from 27 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. If you're weighing up whether you're likely to qualify, our guide on how to get approved for Wegovy walks through what prescribers are looking for and how the assessment process works.

BMI alone doesn't determine outcome. Your prescriber looks at the full picture: your health history, current medicines, any conditions that would make treatment unsuitable, and whether the starting dose and titration schedule make sense for you. Certain medicines interact with semaglutide in ways worth discussing; oral contraceptives and some other medications may be affected by slower gastric emptying, so NHS England's guidance on weight-management injections advises patients to raise this with their prescriber before starting.

Treatment is not suitable during pregnancy, while breastfeeding, or for anyone trying to conceive. If any of those situations apply, your prescriber will discuss this with you at assessment. Once you've started, our page on how to get the best out of Wegovy covers the practical steps, from diet and activity to managing side effects, that support the strongest possible results. For a broader look at which treatment options might suit your situation, our treatment page is the right place to start.